Key facts
- It has raised $21.7M; the latest was Early Stage VC ($12.4M) in Apr 2024.
- Notable investors include Tech Incubator Program for Startup, Mirae Asset Capital, Shinhan Capital, UTC Investment, Timefolio Asset Management — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Avelos Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Avelos Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avelos Therapeutics
Developer of biomarker-driven anti-cancer targeted therapies intended for cancer treatment. The company is developing targeted, biomarker-driven once-therapeutics focused on the areas of cell cycle regulation, DNA damage response and undruggable cancer targets, enabling doctors to effectively treat cancer.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2021
- Employees
- 24
- Website
- avelostx.com/
- Ownership
- Privately Held (backing)
Avelos Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avelos Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avelos Therapeutics in its N-PORT filings yet. We sweep new filings monthly.